According to IVERIC bio's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -22.6989. At the end of 2022 the company had a P/E ratio of -14.1.
Year | P/E ratio | Change |
---|---|---|
2022 | -14.1 | -4.8% |
2021 | -14.8 | 144.11% |
2020 | -6.06 | -1.8% |
2019 | -6.17 | -861.29% |
2018 | 0.8108 | -17.36% |
2017 | 0.9811 | -210.71% |
2016 | -0.8862 | -96.56% |
2015 | -25.7 | 108.3% |
2014 | -12.4 | 790.67% |
2013 | -1.39 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | -4.37 | -80.76% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.